Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-56011 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ARL7 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: GIIYVVDSVD VDRLEEAKTE LHKVTKFAEN QGTPLLVIAN KQDLPKSLPV AEIEKQLALH ELIPATTYHV QPACAIIGEG LTEGMDKLYE MILKRRKSLK QKKKR Highest antigen sequence identity to the following orthologs: Mouse - 100%, Rat - 64%.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.2 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references ATF3 Demethylation Promotes the Transcription of ARL4C, Which Acts as a Tumor Suppressor in Human Breast Cancer.
Li L, Sun RM, Jiang GQ
OncoTargets and therapy 2020;13:3467-3476
OncoTargets and therapy 2020;13:3467-3476
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of ARL7 in human cell line U-2197 using a ARL7 Polyclonal Antibody (Product # PA5-56011).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent staining of ARL7 in human cell line A-431 shows positivity in plasma membrane. Samples were probed using an ARL7 Polyclonal Antibody (Product # PA5-56011).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Methylation of ATF3 decreased the expression of ATF3 and ARL4C. ( A ) Methylation of the ATF3 promoter in breast carcinoma tissues and adjacent normal controls. The red font represents the relative methylation value of all CpG sites in each sample. ( B ) Methylation of the ATF3 promoter in human breast cancer cell lines. ( C ) Dual-luciferase assay in HEK293T cells treated with or without 5'-Aza-dC. ( D and E ) Western blotting analysis of the expression of ATF3 and ARL4C in two human breast cancer cell lines treated with 5'-Aza-dC. *P < 0.05, **P < 0.01 for t -test, n >= 3. Abbreviations: TNBC, triple negative breast cancer; GAPHD, glyceraldehydes-3-phosphate dehydrogenase; pLVX, pLVX puro; DMSO, dimethyl sulfoxide; CpG, cytosine-phosphoric acid-guanine.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Expression of ARL4C in human breast cancer. ( A ) Expression levels of ARL4C were evaluated using qRT-PCR in breast carcinoma and adjacent normal tissues (n=15). ( B ) The protein level of ARL4C in breast carcinoma tissues and adjacent normal controls. ( C ) Hematoxylin and eosin staining, and IHC results for ARL4C. ( D ) Analysis of ARL4C expression in 1218 breast cancer samples. ( E ) Kaplan-Meier plots were constructed for 3951 breast cancer patients stratified by the expression of ATF3 (low = 1998, high = 1953). *P < 0.05, **P < 0.01, ***P < 0.001, n >= 3. Abbreviations: GAPHD, glyceraldehydes-3-phosphate dehydrogenase; HE, hematoxylin and eosin; HR, hazard ratio; IHC, immunohistochemical.
